Medical Weight Management FAQ

GLP-1 and GIP are natural hormones your body makes to help manage blood sugar and appetite. Medications that target these hormones can help people with type 2 diabetes, insulin resistance and weight challenges gain better control over their metabolism - and feel better in the process. These medications don't just treat symptoms, they support your metabolism at its root. They help you: Lose weight in a sustainable way Reduce cravings and overeating Improve blood sugar control Lower risk of heart disease & complications from diabetes

GLP-1 (Glugacon-Like Peptide-1): A hormone released in your gut when you eat Helps the pancreas release insulin (lowers blood sugar) Slows down how quickly the stomach empties (feel full longer) Sends signals to the brain to reduce hunger GLP-1 medications mimic this natural hormone. They help with appetite control, balancing blood sugar and losing weight - all with the goal of helping the body function efficiently. GIP (Glucose Dependent Insulinotropic Polypeptide): A hormone that works alongside GLP-1 Stimulates insulin release Helps regulate fat metabolism Boosts how the body uses energy and stores fat Some medications combine GLP-1 and GIP activity to provide more powerful effects on blood sugar and weight loss.

Yes, these medications are generally well-tolerated and have been FDA-approved for conditions including type 2 diabetes and obesity.Like all medications, they can have side effects. The most common include nausea and constipation, especially at the start, which are easily treated with supplements or over-the-counter medicines.Your practitioner will work with you to ensure continued progress, monitor for any concerns, and help you treat any mild side effects you experience.

Semaglutide and tirzepatide are medications used in metabolic and obesity medicine. Both influence hormones that regulate appetite and blood sugar. Semaglutide works by activating the GLP-1 receptor, which increases satiety and slows gastric emptying. Tirzepatide activates both GLP-1 and GIP receptors which additionally impacts insulin secretion, appetite regulation and metabolic control. Because of this dual mechanism, tirzepatide is often described as a dual incretin therapy. Both medications are administered as once-weekly injections under medical supervision.

Clinical trials show that both medications can support meaningful weight reduction when combined with lifestyle care. Some research suggests that tirzepatide produces greater average weight reduction in clinical trials.However, response varies widely between individuals. Genetics, metabolic health, insulin resistance, sleep, and nutrition all influence outcomes.For this reason, medical providers often select therapy based on medical history, tolerability, and treatment goals.